Brokers Offer Predictions for Corcept Therapeutics Incorporated’s Q4 2025 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORTFree Report) – Research analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a report released on Wednesday, May 29th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.39 per share for the quarter, down from their prior estimate of $0.41. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.95 per share.

Corcept Therapeutics (NASDAQ:CORTGet Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.21 by $0.04. Corcept Therapeutics had a net margin of 22.38% and a return on equity of 24.19%. The business had revenue of $146.80 million for the quarter, compared to analyst estimates of $141.19 million. During the same period in the previous year, the firm earned $0.14 EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year.

Other research analysts also recently issued reports about the company. Truist Financial lifted their price objective on Corcept Therapeutics from $42.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Corcept Therapeutics in a report on Wednesday, May 29th. Finally, StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 3rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Corcept Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $40.10.

Read Our Latest Research Report on Corcept Therapeutics

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $30.17 on Monday. The firm’s 50-day moving average is $25.62 and its two-hundred day moving average is $25.39. The company has a market capitalization of $3.14 billion, a PE ratio of 28.46 and a beta of 0.50. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $34.28.

Insiders Place Their Bets

In other news, insider Gary Charles Robb sold 11,000 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $30.39, for a total transaction of $334,290.00. Following the sale, the insider now owns 20,203 shares in the company, valued at $613,969.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Corcept Therapeutics news, insider Gary Charles Robb sold 11,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $30.39, for a total value of $334,290.00. Following the completion of the sale, the insider now owns 20,203 shares in the company, valued at approximately $613,969.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sean Maduck sold 17,219 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $25.00, for a total transaction of $430,475.00. Following the transaction, the insider now owns 75,222 shares in the company, valued at $1,880,550. The disclosure for this sale can be found here. In the last three months, insiders sold 130,372 shares of company stock valued at $3,493,515. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Fox Run Management L.L.C. purchased a new position in shares of Corcept Therapeutics in the 3rd quarter worth $220,000. Barclays PLC lifted its stake in shares of Corcept Therapeutics by 3.2% in the 3rd quarter. Barclays PLC now owns 73,986 shares of the biotechnology company’s stock valued at $2,016,000 after purchasing an additional 2,299 shares in the last quarter. Swiss National Bank lifted its stake in shares of Corcept Therapeutics by 1.0% in the 3rd quarter. Swiss National Bank now owns 189,765 shares of the biotechnology company’s stock valued at $5,170,000 after purchasing an additional 1,800 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Corcept Therapeutics by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 861,333 shares of the biotechnology company’s stock worth $23,467,000 after purchasing an additional 17,636 shares during the period. Finally, Burney Co. raised its holdings in Corcept Therapeutics by 40.2% in the third quarter. Burney Co. now owns 401,263 shares of the biotechnology company’s stock valued at $10,932,000 after buying an additional 115,006 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

See Also

Earnings History and Estimates for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.